Video

AustinPx Capacity Update July 2024: Small Molecule Finished Dosage Form

Source: AustinPx

AustinPx was founded to help developers realize the full potential of their drug candidates. There are many obstacles to bringing a drug to market, including poor bioavailability and accelerated timelines. That’s where we come in. Our client-centric approach is designed to simplify the complexity of outsourcing and our team of formulation, analytical and manufacturing experts work with you to overcome challenges and identify opportunities to do more, faster.

As the inventors of KinetiSol™ Technology, a next-generation amorphous solid dispersion (ASD) technology for poorly soluble APIs, with its smaller footprint, broader design space, and greener processing solutions, we aim to disrupt the ASD industry. From poor solubility to accelerated timelines, drug development is inherently complex. Effective communication and flexible processes can simplify your path to the market. That is why AustinPx has developed a client-centric approach to contract development and manufacturing services. We are driven by our client’s success and intentional about differentiating ourselves through flexibility and responsiveness, and consultative, unbiased, solutions-driven development services.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online